Radar›Companies›Pharmaceutical Preparations Stocks in USA: Revenue Cohort 11
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Revenue Cohort 11

A five-company pharmaceutical preparations cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderSyndax · 61
Strongest available pathRhythm Pharmaceuticals · +765.0%
Widest latest marginCryoport · 44.4%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1SNDX · Nasdaq

Syndax

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2005Waltham, Massachusetts$1.73B market cap
View full Companies Radar profile
61Moderate
Snapshot price$19.54as of page date
Monthly-close return+15.3%five-year window
FY2025 revenue$0.17BSyndax Pharmaceuticals Inc
Net margin-165.6%FY2025
P/E snapshot-23.9xone ratio, not a verdict
Prism attention20.8%share across these five
Filing track recordRevenue, USD billions
+11261.4%
$0$0.1B$0.1B$0.2BFY2020: $0.002BFY2021: $0.140BFY2022: $0.140BFY2024: $0.024BFY2025: $0.172B20202021202220242025
FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 226.5%
52-week position52% through range
$12.99$25.59
News mentions1.1K
Community mentions11partial coverage
U.S.-scope patents198
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal87/100
Management stability90/100
Market position10/100
Capital-event signal69/100
Innovation pulse23/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 4 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2PHAT · Nasdaq

Phathom Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2019Menlo Park, California$742.7M market cap
View full Companies Radar profile
49Cautious
Snapshot price$9.18as of page date
Monthly-close return-74.9%five-year window
FY2025 revenue$0.17BPhathom Pharmaceuticals, Inc.
Net margin-126.3%FY2025
P/E snapshot8.3xone ratio, not a verdict
Prism attention12.7%share across these five
Filing track recordRevenue, USD billions
+25576.0%
$0$0.1B$0.1B$0.2BFY2023: $0.001BFY2024: $0.055BFY2025: $0.175B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1502.4%
52-week position10% through range
$8.21$18.31
News mentions651
Community mentions14partial coverage
U.S.-scope patents1
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal81/100
Management stability90/100
Market position0/100
Capital-event signal34/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3RYTM · Nasdaq

Rhythm Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Boston, Massachusetts$7.35B market cap
View full Companies Radar profile
49Cautious
Snapshot price$107.2as of page date
Monthly-close return+765.0%five-year window
FY2025 revenue$0.19BRHYTHM PHARMACEUTICALS, INC.
Net margin-103.6%FY2025
P/E snapshot-174.5xone ratio, not a verdict
Prism attention19.9%share across these five
Filing track recordRevenue, USD billions
+145.1%
$0$0.1B$0.1B$0.2BFY2023: $0.077BFY2024: $0.130BFY2025: $0.190B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 56.5%
52-week position68% through range
$74.50$122.2
News mentions1.0K
Community mentions21partial coverage
U.S.-scope patents193
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal71/100
Management stability90/100
Market position10/100
Capital-event signal55/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4CYRX · Nasdaq

Cryoport

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2019Brentwood, Tennessee$814.9M market cap
View full Companies Radar profile
48Cautious
Snapshot price$16.09as of page date
Monthly-close return-73.9%five-year window
FY2025 revenue$0.18BCryoport, Inc.
Net margin44.4%FY2025
P/E snapshot-24.3xone ratio, not a verdict
Prism attention18.2%share across these five
Filing track recordRevenue, USD billions
-20.9%
$0$0.1B$0.2B$0.2BFY2020: $0.223BFY2022: $0.237BFY2023: $0.233BFY2024: $0.228BFY2025: $0.176B20202022202320242025
FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2020, FY2022, FY2023 · CAGR -5.7%
52-week position88% through range
$7.61$17.20
News mentions933
Community mentions0partial coverage
U.S.-scope patents240
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal57/100
Management stability90/100
Market position15/100
Capital-event signal64/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 18 M&A involvements, 0 asset-acquisition events and 12 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5VNDA · Nasdaq

Vanda Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2003Washington, DC, District of Columbia$319.8M market cap
View full Companies Radar profile
38Cautious
Snapshot price$5.29as of page date
Monthly-close return-67.5%five-year window
FY2025 revenue$0.22BVanda Pharmaceuticals Inc.
Net margin-102.0%FY2025
Prism attention28.4%share across these five
Filing track recordRevenue, USD billions
-19.6%
$0$0.1B$0.2B$0.3BFY2021: $0.269BFY2022: $0.254BFY2023: $0.193BFY2024: $0.199BFY2025: $0.216B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -5.3%
52-week position18% through range
$4.27$9.94
News mentions1.5K
Community mentions0partial coverage
U.S.-scope patents1026
Prism Insights

What sits behind the readiness signal

Observed risk 10/100higher means more observed risk
Earnings signal49/100
Management stability90/100
Market position14/100
Capital-event signal41/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 16 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 4 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Rhythm Pharmaceuticals
+765.0%
Syndax
+15.3%
Vanda Pharmaceuticals
-67.5%
Cryoport
-73.9%
Phathom Pharmaceuticals
-74.9%

Latest revenue

USD billions, official filing scope shown on each company card.

Vanda Pharmaceuticals
$0.22B
Rhythm Pharmaceuticals
$0.19B
Cryoport
$0.18B
Phathom Pharmaceuticals
$0.17B
Syndax
$0.17B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Cryoport
44.4%
Vanda Pharmaceuticals
-102.0%
Rhythm Pharmaceuticals
-103.6%
Phathom Pharmaceuticals
-126.3%
Syndax
-165.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Vanda Pharmaceuticals
28.4%
Syndax
20.8%
Rhythm Pharmaceuticals
19.9%
Cryoport
18.2%
Phathom Pharmaceuticals
12.7%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Vanda Pharmaceuticals leads the conversation

It holds 28.4% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.22B.

Price path

Rhythm Pharmaceuticals leads the available price paths

Its monthly-close return is +765.0% for the five-year window. At the other end, Phathom Pharmaceuticals is -74.9% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Cryoport has the widest latest margin

Its FY2025 net margin is 44.4%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Rhythm Pharmaceuticals shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -174.5x while its five-year window price return is +765.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · SNDX

Syndax

1,067available Prism news records

Prism top themes

Price action & investor response
88
Earnings & financial performance
46
Capital allocation & transactions
31
Legal, arbitration & regulatory
16
Leadership & governance
8

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-24.5%166 latest 12m vs 220 prior 12m
2024-01: 5 mentions2024-02: 13 mentions2024-03: 13 mentions2024-04: 5 mentions2024-05: 15 mentions2024-06: 13 mentions2024-07: 11 mentions2024-08: 20 mentions2024-09: 10 mentions2024-10: 13 mentions2024-11: 41 mentions2024-12: 7 mentions2025-01: 17 mentions2025-02: 60 mentions2025-03: 10 mentions2025-04: 15 mentions2025-05: 13 mentions2025-06: 3 mentions2025-07: 6 mentions2025-08: 14 mentions2025-09: 21 mentions2025-10: 16 mentions2025-11: 15 mentions2025-12: 13 mentions2026-01: 9 mentions2026-02: 19 mentions2026-03: 14 mentions2026-04: 19 mentions2026-05: 13 mentions2026-06: 7 mentions2024-012026-06

Machine-classified coverage tone

98.7% positive+6.7 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 22stock performance 22share price 19gene therapy rare diseases 12rare disease treatment 11leukemia driver mutations 11cytogenetic abnormalities leukemia 6phase iii trial 6

Keyword tag occurrences in available Prism news records.

Coverage: 2010-05-24–2026-06-13 · trend and themes shown through 2026-06
Areas of research · RYTM

Rhythm Pharmaceuticals

1,023available Prism news records

Prism top themes

Price action & investor response
104
Legal, arbitration & regulatory
43
Capital allocation & transactions
30
Earnings & financial performance
21
Leadership & governance
12

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+34.0%280 latest 12m vs 209 prior 12m
2024-01: 13 mentions2024-02: 9 mentions2024-03: 5 mentions2024-04: 13 mentions2024-05: 8 mentions2024-06: 13 mentions2024-07: 14 mentions2024-08: 8 mentions2024-09: 10 mentions2024-10: 7 mentions2024-11: 13 mentions2024-12: 13 mentions2025-01: 11 mentions2025-02: 36 mentions2025-03: 23 mentions2025-04: 47 mentions2025-05: 16 mentions2025-06: 11 mentions2025-07: 12 mentions2025-08: 21 mentions2025-09: 13 mentions2025-10: 10 mentions2025-11: 26 mentions2025-12: 24 mentions2026-01: 32 mentions2026-02: 35 mentions2026-03: 34 mentions2026-04: 34 mentions2026-05: 32 mentions2026-06: 7 mentions2024-012026-06

Machine-classified coverage tone

88.6% positive-3.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 40stock performance 24orphan drug pricing 20share price 13obesity pharmacotherapy 13market reaction 13semaglutide obesity 12orphan drug incentives 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-12–2026-06-19 · trend and themes shown through 2026-06
Areas of research · CYRX

Cryoport

933available Prism news records

Prism top themes

Price action & investor response
56
Earnings & financial performance
40
Legal, arbitration & regulatory
9
Capital allocation & transactions
3

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+35.8%148 latest 12m vs 109 prior 12m
2024-01: 0 mentions2024-02: 15 mentions2024-03: 12 mentions2024-04: 3 mentions2024-05: 3 mentions2024-06: 9 mentions2024-07: 3 mentions2024-08: 5 mentions2024-09: 2 mentions2024-10: 23 mentions2024-11: 7 mentions2024-12: 3 mentions2025-01: 7 mentions2025-02: 5 mentions2025-03: 16 mentions2025-04: 23 mentions2025-05: 9 mentions2025-06: 6 mentions2025-07: 2 mentions2025-08: 7 mentions2025-09: 12 mentions2025-10: 9 mentions2025-11: 7 mentions2025-12: 16 mentions2026-01: 21 mentions2026-02: 17 mentions2026-03: 19 mentions2026-04: 17 mentions2026-05: 17 mentions2026-06: 4 mentions2024-012026-06

Machine-classified coverage tone

94.4% positive+0.0 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 36stock price 12stem cell banking 10stock indices 8stock surge 8stock plunge 7gene delivery systems 7equity markets 6

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-06-12 · trend and themes shown through 2026-06
Areas of research · VNDA

Vanda Pharmaceuticals

1,461available Prism news records

Prism top themes

Legal, arbitration & regulatory
69
Price action & investor response
48
Macro demand & rates
42
Capital allocation & transactions
35
Earnings & financial performance
19

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+22.1%354 latest 12m vs 290 prior 12m
2023-12: 0 mentions2024-01: 14 mentions2024-02: 11 mentions2024-03: 19 mentions2024-04: 29 mentions2024-05: 20 mentions2024-06: 23 mentions2024-07: 10 mentions2024-08: 7 mentions2024-09: 13 mentions2024-10: 28 mentions2024-11: 15 mentions2024-12: 13 mentions2025-01: 22 mentions2025-02: 98 mentions2025-03: 14 mentions2025-04: 25 mentions2025-05: 22 mentions2025-06: 10 mentions2025-07: 6 mentions2025-08: 16 mentions2025-09: 19 mentions2025-10: 25 mentions2025-11: 43 mentions2025-12: 44 mentions2026-01: 35 mentions2026-02: 48 mentions2026-03: 17 mentions2026-04: 48 mentions2026-05: 43 mentions2023-122026-05

Machine-classified coverage tone

79.8% positive-3.0 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

ssri effectiveness trials 21stock price 19stock performance 15generic drug approval 14treatment-resistant depression studies 11psychotropic adverse reactions 8share price 8pharmacoepidemiology 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-05-29 · trend and themes shown through 2026-05
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

SNDX

Syndax

through 2026-05-01
Earnings releases 32Company announcements 31Leadership changes 8Listing / IPO 6Regulatory 3
  1. Earnings releases

    Chief Financial Officer Keith Goldan said total revenue was $64.9 million in the quarter, up 224% year-over-year.

  2. Company announcements

    Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted inducement awards to purchase up to 15,500 shares of common stock to one new employee under the Company's 2023 Inducement Plan.

  3. M&A

    KBC Group NV boosted its position in shares of Syndax Pharmaceuticals by 104.8% in the fourth quarter. KBC Group NV now owns 6,954 shares of the company’s stock worth $92,000 after acquiring an additional 3,559 shares during the last quarter.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PHAT

Phathom Pharmaceuticals

through 2026-05-03
Earnings releases 18Company announcements 3Leadership changes 3Board updates 1Regulatory 1
  1. Earnings releases

    Phathom Pharmaceuticals (NASDAQ:PHAT) reported first-quarter 2026 net revenue of $58.3 million, more than doubling the $28.5 million recorded in the same period a year ago, as the company emphasized continued progress in deepening adoption of its acid-suppression medicine VOQUEZNA among gastroenterologists.

  2. Leadership changes

    Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer.

  3. Regulatory

    A key upcoming event is the FDA’s decision on the Citizens’ Petition, expected in early June, which is seen as a significant catalyst for the stock.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RYTM

Rhythm Pharmaceuticals

through 2026-03-31
Earnings releases 15M&A 3
  1. Earnings releases

    The company had revenue of $57.25 million for the quarter, compared to analyst estimates of $56.16 million.

  2. M&A

    State of Wyoming bought a new position in shares of Rhythm Pharmaceuticals in the second quarter valued at approximately $67,000.

  3. M&A

    Bayforest Capital Ltd now owns 1,171 shares of the company’s stock worth $118,000 after acquiring an additional 1,055 shares during the period.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CYRX

Cryoport

through 2026-05-04
Earnings releases 25M&A 4Business contracts 1Company announcements 1Lawsuits 1
  1. Earnings releases

    Cryoport delivered a strong start to 2026 with first-quarter revenue of $47.8 million , up 16% year-over-year.

  2. M&A

    Cryoport, Inc, a temperature-controlled supply chain solution provider for the life sciences industry, has obtained Cell&Co BioServices, a bioservices business that offers biorepository, kitting, and logistics services to the same sector. The purchase price was $6.7 million.

  3. Company announcements

    Cryoport has outlined aggressive expansion plans. Mark Sawicki, President and CEO of Cryoport Systems, told gasworld that it plans to open two new facilities in Houston and Belgium in the second and third quarters, with more expansion to come.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VNDA

Vanda Pharmaceuticals

through 2026-03-21
Earnings releases 29M&A 16Regulatory 5Lawsuits 3Business contracts 1
  1. Earnings releases

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vanda Pharmaceuticals $216.10 million 1.93 -$220.47 million ($3.73) -1.89

  2. Regulatory

    Vanda Pharmaceuticals agreed to a brief FDA-requested extension of the expedited re-review for the clinical hold on tradipitant in motion sickness. The new target date is December 5, 2025.

  3. Lawsuits

    a federal lawsuit against the U.S. FDA

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 51–58. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Vanda Pharmaceuticals has the widest attention-readiness rank gap

It ranks #1 by measured news attention (28.4%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Vanda Pharmaceuticals in Companies Radar

Phathom Pharmaceuticals shows a price-operating divergence to inspect

Its displayed filing-revenue change is +25576.0% while its available monthly-close return is -74.9%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Phathom Pharmaceuticals in Companies Radar
Explanations

Attention measures coverage volume, not quality

Vanda Pharmaceuticals's 28.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Vanda Pharmaceuticals in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Syndax's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 61/100 score.

Open Syndax in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon